<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00614848</url>
  </required_header>
  <id_info>
    <org_study_id>IP034</org_study_id>
    <nct_id>NCT00614848</nct_id>
  </id_info>
  <brief_title>The ENDEAVOR II Clinical Trial: The Medtronic Endeavor Drug Eluting Coronary Stent System in Coronary Artery Lesions</brief_title>
  <acronym>ENDEAVOR II</acronym>
  <official_title>Randomized Controlled Trial to Evaluate the Safety and Efficacy of the Medtronic AVE ABT-578 Eluting Driver Coronary Stent in De Novo Native Coronary Artery Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Vascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Vascular</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate the safety and efficacy of the Driver Coronary Stent coated with 10 mcg/mm&#xD;
      ABT-578 compared to the uncoated Driver Stent for the treatment of single de novo lesions in&#xD;
      native coronary arteries 2.25-3.5 mm in diameter.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2003</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">January 2005</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Target Vessel Failure Rate at 9 months post procedure</measure>
    <time_frame>9 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Device Success Lesion Success Procedure Success Major Cardiac Adverse Events (MACE) at 30 days and 6, 9, and 12 months, and annually thereafter out to 5 years. Late loss at 8 months as measured by QCA</measure>
    <time_frame>30 days and 6, 9, and 12 months, and annually thereafter out to 5 years.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1200</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Arterial Occlusive Diseases</condition>
  <condition>Coronary Disease</condition>
  <condition>Coronary Arteriosclerosis</condition>
  <condition>Heart Diseases</condition>
  <condition>Myocardial Ischemia</condition>
  <condition>Vascular Diseases</condition>
  <condition>Ischemia</condition>
  <condition>Arteriosclerosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Endeavor Drug Eluting Coronary Stent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Driver bare-metal coronary stent</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Endeavor drug eluting coronary stent</intervention_name>
    <description>Zotarolimus coated coronary stent (10ug/mm)</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject is an acceptable candidate for PTCA, stenting, and emergent CABG.&#xD;
&#xD;
          -  Subject must have clinical evidence of ischemic heart disease or a positive functional&#xD;
             study.&#xD;
&#xD;
          -  Subject has single vessel disease or has multivessel disease with only moderate&#xD;
             stenosis (max 50-60% or total occlusion (100%) for which no interventions are planned&#xD;
             at the time of study inclusion).&#xD;
&#xD;
          -  Target lesion / vessel must meet the following criteria:&#xD;
&#xD;
               1. Target lesion is a single de novo lesion that has not been previously treated&#xD;
                  with any interventional procedure. Only one lesion may be treated per subject&#xD;
&#xD;
               2. Target vessel must be a native coronary artery with a stenosis of &gt;=50% and &lt;100%&#xD;
&#xD;
               3. Target lesion must be &gt;= 14 mm and ≤ 27 mm in length&#xD;
&#xD;
               4. Target vessel reference diameter must be &gt;= 2.25 mm and ≤3.5 mm&#xD;
&#xD;
          -  Female subjects of childbearing potential must have a negative pregnancy test within 7&#xD;
             days before the procedure.&#xD;
&#xD;
          -  Subject or subject's legal representative has been informed of the nature of the study&#xD;
             and agrees to its provisions and has provided written informed consent as approved by&#xD;
             the Institutional Review Board/Ethics Committee of the respective clinical site&#xD;
&#xD;
          -  Subject and treating physician agree that subject will comply with all required&#xD;
             post-procedure follow-up&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A documented left ventricular ejection fraction &lt;30%&#xD;
&#xD;
          -  A known hypersensitivity or contraindication to aspirin, heparin, clopidogrel, cobalt,&#xD;
             nickel, chromium, or a sensitivity to contrast media, which cannot be adequately&#xD;
             pre-medicated&#xD;
&#xD;
          -  History of an allergic reaction or significant sensitivity or receiving drugs similar&#xD;
             to/or synergistic to ABT-578 (rapamycin, tacrolimus, sirolimus, CCI-779 or other&#xD;
             analogues).&#xD;
&#xD;
          -  A platelet count &lt;100,000 cells/mm³ or &gt;700,000 cells/mm³, or a WBC &lt;3,000 cells/mm³&#xD;
&#xD;
          -  Evidence of an acute myocardial infarction within 72 hours of the intended treatment&#xD;
             (defined as: Q wave or non-Q wave infarction having CK enzymes &gt;2X the upper&#xD;
             laboratory normal with the presence of a CK-MB elevated above the Institution's upper&#xD;
             limit of normal).&#xD;
&#xD;
          -  Creatinine &gt;2.0 mg/dl&#xD;
&#xD;
          -  A previous coronary interventional procedure of any kind within the 30 days prior to&#xD;
             the procedure&#xD;
&#xD;
          -  Subject requires planned interventional treatment of either the target or any&#xD;
             non-target vessel within 30 days post-procedure&#xD;
&#xD;
          -  Target lesion requires treatment with a device other than PTCA prior to stent&#xD;
             placement&#xD;
&#xD;
          -  Previous stenting anywhere in the target vessel&#xD;
&#xD;
          -  Target vessel has evidence of thrombus or is excessively tortuous (2 bends &gt;90 degrees&#xD;
             to reach the target lesion)&#xD;
&#xD;
          -  Significant (&gt;50%) stenosis proximal or distal to the target lesion that might require&#xD;
             revascularization or impede run off&#xD;
&#xD;
          -  Target lesion located in native vessel distally to anastomosis with vein graft or LIMA&#xD;
&#xD;
          -  Target lesion has any of the following characteristics:&#xD;
&#xD;
               1. Lesion location is aorto-ostial, an unprotected left main lesion, or within 5mm&#xD;
                  of the origin of the LAD, LCX, or RCA&#xD;
&#xD;
               2. Involves a side branch &gt;2.0 mm in diameter&#xD;
&#xD;
               3. Is at or distal to a 45º bend in the vessel&#xD;
&#xD;
               4. Is severely calcified&#xD;
&#xD;
          -  Unprotected left main coronary artery disease (an obstruction greater than 50% in the&#xD;
             left main coronary artery)&#xD;
&#xD;
          -  History of a stroke or transient ischemic attack within the prior 6 months&#xD;
&#xD;
          -  Active peptic ulcer or upper GI bleeding within the prior 6 months&#xD;
&#xD;
          -  The subject has a history of bleeding diathesis or coagulopathy or will refuse blood&#xD;
             transfusions&#xD;
&#xD;
          -  Concurrent medical condition with a life expectancy of less than 12 months&#xD;
&#xD;
          -  Any previous or planned treatment with anti-restenotic therapies including, but not&#xD;
             limited to, drug-eluting stents and brachytherapy&#xD;
&#xD;
          -  Currently participating in an investigational drug or another device study that has&#xD;
             not completed the primary endpoint or that clinically interferes with the current&#xD;
             study endpoints&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J. Fajadet, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinique Pasteur, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard E Kuntz, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Harvard Medical School, USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>W. Wijns, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>OLV Hospital, Belgium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dr. J. Fajedet</name>
      <address>
        <city>Clinique Pasteur</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Fajadet J, Wijns W, Laarman GJ, Kuck KH, Ormiston J, Münzel T, Popma JJ, Fitzgerald PJ, Bonan R, Kuntz RE; ENDEAVOR II Investigators. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation. 2006 Aug 22;114(8):798-806. Epub 2006 Aug 14.</citation>
    <PMID>16908773</PMID>
  </results_reference>
  <verification_date>April 2011</verification_date>
  <study_first_submitted>January 30, 2008</study_first_submitted>
  <study_first_submitted_qc>January 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2008</study_first_posted>
  <last_update_submitted>April 8, 2011</last_update_submitted>
  <last_update_submitted_qc>April 8, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 11, 2011</last_update_posted>
  <responsible_party>
    <name_title>Judith L. Jaeger, Director of Clinical Research</name_title>
    <organization>Medtronic Vascular</organization>
  </responsible_party>
  <keyword>restenosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Arteriosclerosis</mesh_term>
    <mesh_term>Arterial Occlusive Diseases</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

